Kala Bio, Inc. (KALA): Total Liabilities
$2.49M
As of 2025-12-31
$1.54M
As of 2026-06-30
-66.8%
3-year compound annual growth
-54.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.49M | -94.2% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $43.15M | -10.9% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $48.45M | -28.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $67.85M | -44.7% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $122.62M | +0.8% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $121.61M | -2.4% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $124.63M | +7.5% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $115.99M | +331.7% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $26.87M | n/c | 2019-03-12, Balance as of period end |
| 2016-12-31 | $15.70M | n/a | 2018-04-02, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare KALA, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗